MedTrace Logo

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

NCT05153330 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-07-03

No results posted yet for this study

Summary

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

Conditions

Interventions

DRUG

BMF-219

BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.

Sponsors & Collaborators

  • Biomea Fusion Inc.

    lead INDUSTRY

Principal Investigators

  • Steve Morris, MD · Biomea Fusion Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2025-02-13
Completion
2025-05-02
FDA Drug
Yes

Countries

  • United States
  • Greece
  • Italy
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05153330 on ClinicalTrials.gov